A study of the efficacy and toxicity outcomes of extended durvalumab dosing in patients with stage III unresectable non-small cell lung cancer (NSCLC) during the COVID-19 pandemic

BACKGROUND: Durvalumab following chemoradiation in unresectable stage III non-small cell lung cancer (NSCLC) has led to improved outcomes. The schedule of administration has been determined by pharmacokinetic studies. This study evaluates real-world efficacy and safety outcomes of extended dosing (E...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanna, Lilian, Moffat, Gordon Taylor, Hopman, Wilma, Gaudreau, Pierre-Olivier, Fung, Andrea S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801690/
https://www.ncbi.nlm.nih.gov/pubmed/36608489
http://dx.doi.org/10.1016/j.ctarc.2022.100678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801690/
https://www.ncbi.nlm.nih.gov/pubmed/36608489
http://dx.doi.org/10.1016/j.ctarc.2022.100678

Ejemplares similares